Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IgLON family member 5 is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein of the immunoglobulin superfamily, found primarily in neurons and oligodendrocytes but also expressed in skeletal muscle and some non-neural tissues[1][2][3][4]. Like other IgLONs, it forms homophilic or heterophilic complexes and is essential for cell adhesion, neuronal migration, axon guidance, and muscle cell differentiation and regeneration[1][2][3]. Pathogenic autoantibodies targeting IgLON5 underlie anti-IgLON5 disease, a rare neurodegenerative tauopathy characterized by sleep disorders and neuronal cytoskeletal pathology, suggesting a crucial, multifaceted role in nervous system and muscle integrity[3][4]. There are currently no approved drugs targeting IgLON5 directly; however, IgLON5 antibodies serve as important diagnostic biomarkers for the corresponding autoimmune syndrome[3][4][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IgLON family member 5 (IGLON5).